977 related articles for article (PubMed ID: 26494391)
41. Individualization of lymph node dissection in RET (rearranged during transfection) carriers at risk for medullary thyroid cancer: value of pretherapeutic calcitonin levels.
Machens A; Lorenz K; Dralle H
Ann Surg; 2009 Aug; 250(2):305-10. PubMed ID: 19638924
[TBL] [Abstract][Full Text] [Related]
42. Diagnostic Challenges of Medullary Thyroid Carcinoma.
Leimbach RD; Hoang TD; Shakir MKM
Oncology; 2021; 99(7):422-432. PubMed ID: 33878761
[TBL] [Abstract][Full Text] [Related]
43. Serum Calcitonin-Negative Medullary Thyroid Carcinoma: A Case Series of 19 Patients in a Single Center.
Kim SJ; Yun HJ; Shin SJ; Lee YS; Chang HS
Front Endocrinol (Lausanne); 2021; 12():747704. PubMed ID: 34803914
[TBL] [Abstract][Full Text] [Related]
44. Elevated basal serum levels of calcitonin and simultaneous surgery of MEN2A-specific tumors.
Tang HX; Yang H; Li F; Cao ZL; Huang YT; Qi XP
Neoplasma; 2021 Sep; 68(5):1098-1106. PubMed ID: 34156257
[TBL] [Abstract][Full Text] [Related]
45. Risk Profile of the RET A883F Germline Mutation: An International Collaborative Study.
Mathiesen JS; Habra MA; Bassett JHD; Choudhury SM; Balasubramanian SP; Howlett TA; Robinson BG; Gimenez-Roqueplo AP; Castinetti F; Vestergaard P; Frank-Raue K
J Clin Endocrinol Metab; 2017 Jun; 102(6):2069-2074. PubMed ID: 28323957
[TBL] [Abstract][Full Text] [Related]
46. The prognostic value of lymph node ratio in Medullary thyroid carcinoma: A multi-center study.
Rozenblat T; Hirsch D; Robenshtok E; Grozinsky-Glasberg S; Gross DJ; Mazeh H; Benbassat C; Twito O; Levy S; Mizrachi A; Shpitzer T; Bachar G
Eur J Surg Oncol; 2020 Nov; 46(11):2023-2028. PubMed ID: 32389525
[TBL] [Abstract][Full Text] [Related]
47. Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d'Etudes des Tumeurs a Calcitonine (GETC).
Cohen R; Campos JM; Salaün C; Heshmati HM; Kraimps JL; Proye C; Sarfati E; Henry JF; Niccoli-Sire P; Modigliani E
J Clin Endocrinol Metab; 2000 Feb; 85(2):919-22. PubMed ID: 10690910
[TBL] [Abstract][Full Text] [Related]
48. MIBG for diagnosis and therapy of medullary thyroid carcinoma: is there still a role?
Castellani MR; Seregni E; Maccauro M; Chiesa C; Aliberti G; Orunesu E; Bombardieri E
Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):430-40. PubMed ID: 19088696
[TBL] [Abstract][Full Text] [Related]
49. Carcinoembryonic antigen levels correlated with advanced disease in medullary thyroid cancer.
Turkdogan S; Forest VI; Hier MP; Tamilia M; Florea A; Payne RJ
J Otolaryngol Head Neck Surg; 2018 Sep; 47(1):55. PubMed ID: 30223887
[TBL] [Abstract][Full Text] [Related]
50. The dilemma of metastatic medullary thyroid carcinoma: when to start systemic treatment.
Siano M; Alfieri S; Granata R; Calareso G; Orlandi E; Bergamini C; Locati LD
Tumori; 2019 Dec; 105(6):NP28-NP31. PubMed ID: 30782103
[TBL] [Abstract][Full Text] [Related]
51. Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin.
Tran K; Khan S; Taghizadehasl M; Palazzo F; Frilling A; Todd JF; Al-Nahhas A
Hell J Nucl Med; 2015; 18(1):19-24. PubMed ID: 25679074
[TBL] [Abstract][Full Text] [Related]
52. Recurrent Metastatic Medullary Thyroid Carcinoma: A Case of Sustained Response to Prolonged Treatment with Somatostatin Analogues.
Cano JM; Galán R; López R
Thyroid; 2017 Nov; 27(11):1450-1455. PubMed ID: 28927353
[TBL] [Abstract][Full Text] [Related]
53. Prospective study on the clinical relevance of
Califano I; Pitoia F; Chirico R; De Salazar A; Bastianello MJ
Endocrine; 2022 Jun; 77(1):143-150. PubMed ID: 35489000
[TBL] [Abstract][Full Text] [Related]
54. Can the early reduction of tumour markers predict outcome in surgically treated sporadic medullary thyroid carcinoma?
Bümming P; Ahlman H; Nilsson B; Nilsson O; Wängberg B; Jansson S
Langenbecks Arch Surg; 2008 Sep; 393(5):699-703. PubMed ID: 18626656
[TBL] [Abstract][Full Text] [Related]
55. CALCITONIN SECRETORY INDEX AND UNSUSPECTED NODAL DISEASE IN MEDULLARY THYROID CARCINOMA.
Filimon S; Payne RJ; Black MJ; Hier MP; Mlynarek AM; Forest VI; Tamilia M
Endocr Pract; 2018 May; 24(5):460-467. PubMed ID: 29847167
[TBL] [Abstract][Full Text] [Related]
56. Spontaneous and Treatment-Related Changes of Serum Calcitonin in Medullary Thyroid Cancer: Long-Term Experience in a Patient With Multiple Endocrine Neoplasia Type 2B.
Réti Z; Tabák ÁG; Garami M; Kalina I; Kiss G; Sápi Z; Tóth M; Tőke J
JCO Precis Oncol; 2024 May; 8():e2300675. PubMed ID: 38709988
[TBL] [Abstract][Full Text] [Related]
57. Surgical strategy for the treatment of medullary thyroid carcinoma.
Fleming JB; Lee JE; Bouvet M; Schultz PN; Sherman SI; Sellin RV; Friend KE; Burgess MA; Cote GJ; Gagel RF; Evans DB
Ann Surg; 1999 Nov; 230(5):697-707. PubMed ID: 10561095
[TBL] [Abstract][Full Text] [Related]
58. Dynamic risk stratification for medullary thyroid cancer according to the response to initial therapy.
Kwon H; Kim WG; Jeon MJ; Song DE; Lee YM; Sung TY; Chung KW; Yoon JH; Hong SJ; Baek JH; Lee JH; Kim TY; Kim WB; Shong YK
Endocrine; 2016 Jul; 53(1):174-81. PubMed ID: 26754662
[TBL] [Abstract][Full Text] [Related]
59. Medullary thyroid carcinoma: long-term outcomes of surgical treatment.
Abraham DT; Low TH; Messina M; Jackson N; Gill A; Chou AS; Delbridge L; Learoyd D; Robinson BG; Sidhu S; Sywak M
Ann Surg Oncol; 2011 Jan; 18(1):219-25. PubMed ID: 20878247
[TBL] [Abstract][Full Text] [Related]
60. Surgical management of medullary thyroid cancer.
Mazeh H; Sippel RS
Minerva Endocrinol; 2012 Dec; 37(4):329-34. PubMed ID: 23235189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
